Yield10 Bioscience

Yield10 Bioscience, Inc. operates as an agricultural bioscience company. It focuses on the development of technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. The company was founded by Anthony J. Sinskey, Simon F. Williams and Oliver P. Peoples in June 1992 and is headquartered in Woburn, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company was founded by Anthony J. Sinskey, Simon F. Williams, and Oliver P. Peoples in 1992 and is headquartered in Woburn, MA.

WOBURN, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its second quarter 2021 financial results and provide a corporate update on Wednesday, August 11, 2021.

Yield10 Bioscience to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Wednesday, August 11, 2021

WOBURN, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it has completed planting of its 2021 Field Test and Seed Scale Up program at all contracted sites in the United States, Canada, and Argentina.

Yield10 Bioscience Begins 2021 Field Test and Seed Scale Up Program

—Dr. Munyikwa Appointed as Director of Regulatory Affairs—

Yield10 Bioscience Announces Two New Hires as Camelina Business Plan Advances

WOBURN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the 2021 Synthetic Biology: Engineering, Evolution & Design (SEED) conference, taking place in a virtual format June 15 through June 18, 2021.

Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advances Using Camelina Platform to Produce PHA Bioplastic at 2021 Synthetic Biology: Engineering, Evolution and Design Virtual Conference

WOBURN, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced that Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10, will give a corporate presentation at the LD Micro Virtual Invitational XI investor conference on Wednesday, June 9, 2021 at 3:30 pm ET, Track Two. The virtual conference and presentation will be held via webcast from June 8 to 10, 2021.

Yield10 Bioscience to Present at the LD Virtual Invitational XI on June 9, 2021

Yield10 Bioscience's (YTEN) CEO Oliver Peoples on Q1 2021 Results - Earnings Call Transcript

Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update

Yield10 Bioscience Announces First Quarter 2021 Financial Results

WOBURN, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its first quarter 2021 financial results and provide a corporate update on Tuesday, May 11, 2021.

Yield10 Bioscience to Announce First Quarter 2021 Financial Results and Host a Conference Call on Tuesday, May 11, 2021

Yield10 Bioscience's (YTEN) CEO Oliver Peoples on Q4 2020 Results - Earnings Call Transcript

Yield10 Bioscience Announces Fourth Quarter and Full Year 2020 Financial Results

WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, announces that Chief Executive Officer Oliver Peoples, PhD. will present at Maxim Group's 2021 Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021.

Yield10 Bioscience to Present at Maxim Group's 2021 Inaugural Emerging Growth Virtual Conference

WOBURN, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2020 financial results and provide a corporate update on Tuesday, March 16, 2021.

Yield10 Bioscience to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call on Tuesday, March 16, 2021

WOBURN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced it will be featured as a presenting company at the Bank of America 2021 Virtual Global Agriculture & Materials Conference being held on March 3-4, 2021.

Yield10 Bioscience to Present at Bank of America 2021 Virtual Global Agriculture & Materials Conference on March 4, 2021

WOBURN, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has received proceeds of approximately $3.8 million from the exercise of 472,099 warrants exercised between January 1, 2021 and February 16, 2021, and the Company has issued to investors 472,099 shares of common stock in exchange for the exercised warrants. The warrants were issued to investors pursuant to a public offering that closed on November 19, 2019. Since November 19, 2019, a total of 679,395 warrants issued in the public offering have been exercised for total proceeds of $5.4 million. The Series A and Series B warrants issued in the November 2019 public offering are exercisable at $8.00 per share and have expiration dates of May 19, 2022 and May 19, 2027, respectively.

Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million

WOBURN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share. Gross proceeds before deducting underwriting discounts and commissions and other offering expenses are approximately $12.7 million. Existing investors, including shareholder Jack W. Schuler, as well as institutional and retail investors participated in the offering.

Yield10 Bioscience Announces Closing of $12.7 Million Public Offering

WOBURN, Mass., Jan. 31, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the pricing of its underwritten public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share. The gross proceeds from the public offering will be approximately $12.7 million, the maximum amount currently available to it under the company's shelf registration statement, before deducting underwriting discounts and commissions and estimated offering expenses. Existing investors, including shareholder Jack W. Schuler, as well as institutional and retail investors participated in the offering.

Yield10 Bioscience Announces Pricing of $12.7 Million Public Offering

WOBURN, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it has commenced an underwritten public offering of shares of its common stock. The public offering is subject to market conditions, and there can be no assurance as to whether or when the public offering may be completed, or the actual size or terms of the public offering.

Yield10 Bioscience Announces Proposed Public Offering of Common Stock

Archer-Daniels-Midland Company

Adecoagro

Corteva Inc

4 Agriculture Operations Stocks Countering Challenges Facing the Industry

WOBURN, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced successful field testing of prototype lines of the oilseed Camelina sativa that have been programed to produce PHA bioplastics directly in seed.

Yield10 Bioscience Announces Achievement of Proof-of-Concept Milestone for Producing PHA Bioplastic in Field Grown Camelina Plants

WOBURN, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that Meghna Malik, Ph.D., Senior Director, will present at the 4th CRISPR AgBio Congress which is being held December 1-3, 2020 as a virtual event.

Yield10 Bioscience Researcher Dr. Meghna Malik to Present at the 4th CRISPR AgBio Congress 2020 Virtual Event

Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q3 2020 Results - Earnings Call Transcript

WOBURN, Mass. and HARPENDEN, U.K., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced it has signed a collaboration agreement with UK-based Rothamsted Research to support Rothamsted's Flagship Program to develop omega-3 oils in Camelina sativa. The technology developed by Rothamsted could enable the sustainable, plant-based production of omega-3 (DHA+EPA) nutritional oils that closely mimic the composition of southern hemisphere fish oil, an important ingredient in aquaculture feed. Omega-3 oils are also essential for human nutrition and have demonstrated benefits in heart health.

Yield10 Bioscience Announces Collaboration with Rothamsted Research to Develop Advanced Technology for Producing Omega-3 Nutritional Oils in Camelina

WOBURN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its third quarter 2020 financial results and provide a corporate update on Thursday, November 12, 2020.

Yield10 Bioscience to Announce Third Quarter 2020 Financial Results and Host a Conference Call on Thursday, November 12, 2020

WOBURN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has begun field testing to evaluate the emergence and agronomics of winter Camelina sativa varieties. The testing of these winter varieties in the 2020/2021 winter season is part of Yield10's continued development of Camelina sativa in the medium term for use at commercial scale as a cash cover crop for North America.

Yield10 Bioscience Announces Start of Field Tests of Winter Camelina Varieties

WOBURN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced it has completed the harvest for its 2020 Field Test Program for Camelina and canola trials conducted in the United States and Canada. Yield10’s 2020 Field Test Program is designed to evaluate several novel traits in Camelina and canola, and the Company expects to begin reporting data from the field tests in the fourth quarter of 2020 through early 2021.

Yield10 Bioscience Announces Completion of Harvesting for 2020 Field Test Program to Evaluate Novel Yield and Compositional Traits in Camelina and Canola

News for Yield10 Bioscience Stock (YTEN)